Applying the same criteria to thyroid cancer patients may not be valid due to differences in PSMA uptake in prostate cancer (internalization into tumor cells) compared to thyroid cancer (cell surface binding in the tumor microvasculature); however, eligibility guidelines in the more well-studied prostate cancer population could serve as a useful starting point. The gene discussed is FOLH1; the disease is prostate carcinoma.